Markets

Conatus Soars on Positive Phase II Data on Emricasan - Analyst Blog

A generic image of coins in front of a stock chart.
Credit: Shutterstock photo

Conatus PharmaceuticalsCNAT announced top-line results from a phase II double-blind, placebo-controlled study (n=38) on emricasan, in patients with nonalcoholic fatty liver disease (NAFLD), including a subset of NAFLD patients with nonalcoholic steatohepatitis (NASH).

Results showed a statistically significant reduction in alanine amino transferase (ALT) in patients treated with emricasan (25 mg twice daily) compared to placebo (39% versus 14%). Emricasan-treated patients also achieved a statistically significant reduction on elevated baseline levels of three key serum biomarkers: caspase-cleaved cytokeratin 18 (cCK18), full length cytokeratin 18 and caspase 3/7. The candidate was found to be safe and well-tolerated with no dose-limiting toxicities or serious adverse events being reported.

The company expects to present detailed results from the NAFLD/NASH study at the annual meeting of the European Association for the Study of the Liver in April.

According to the National Institutes of Health, approximately 5.5 million people in the U.S. suffer from chronic liver disease, or cirrhosis. Additionally, the European Association for the Study of the Liver estimates 29 million people in the EU to be suffering from the same disease.

Apart from the NAFLD/NASH study, Conatus is evaluating emricasan in other studies, which include a liver cirrhosis study (phase II, initial results expected in the fourth quarter of 2015), a portal hypertension (PH) study (phase II, top-line results expected in the third quarter of 2015) and a post liver transplant clearance of hepatitis C virus infection with sustained viral response (POLT-HCV-SVR) study (phase IIb, initial results expected in the second quarter of 2015).

We are encouraged by Conatus' efforts to develop emricasan for different types of liver diseases and expect investor focus to remain on further updates. Shares were up 17.4% on the positive top-line data.

Conatus carry a Zacks Rank #2 (Buy). Some better ranked stocks in the health care sector include Lannett Company, Inc. LCI , Cytokinetics Inc. CYTK and Cambrex Corp. CBM . All three companies sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

CONATUS PHARMA (CNAT): Free Stock Analysis Report

CYTOKINETCS INC (CYTK): Free Stock Analysis Report

CAMBREX CORP (CBM): Free Stock Analysis Report

LANNETT INC (LCI): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

HSTO PH CYTK

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More